STUDY Abstract: GS-018 Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens – A. Mangia, et. al.
Study Aims and Results: The study followed patients treated with sofosbuvir-based therapies to understand how treatment and cure affect liver-related health and the risk of further liver disease progression and death.
As of October 5, 2017, 1,564 cirrhotic patients with sofosbuvir-containing therapies were cured and enrolled in the study.
In the long-term – 99.9% of the patients remained cured. The majority of patients with compensated and decompensated cirrhosis showed an improvement in their liver-related disease. So far, there have been 20 liver transplantations and five liver-related deaths. There were 55 cases of liver cancer that mostly occurred in the patients with decompensated cirrhosis. The majority of cirrhotic patients showed improvement in their liver disease.
Conclusion: In this registry of people cured with sofosbuvir-based regimens, the long-term outcomes show improvement in liver-related outcomes. However, people with more advanced liver disease before treatment had liver disease progression even after being cured of HCV.
Editorial Comments: This study is notable because it adds to our knowledge that successful direct-acting antiviral(DAA) treatment has beneficial long-term outcomes.Share This Page